Phase
Condition
Orthopedic Surgery
Dementia
Orthopedics
Treatment
Melatonin 4 mg
Placebo oral tablet
Clinical Study ID
Ages > 70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Demographic criteria: patient 70 years old or older
Diagnostic criteria: isolated fracture of a lower limb
Proximal femoral fractures: head, cervical, or trochanteric fractures
Periprosthetic hip fracture
Femoral shaft fracture
Distal femoral fractures: supracondylar or condylar
Periprosthetic knee fracture
Tibial plateau fracture
Treatments/strategies/procedures: scheduled orthopedic surgery (osteosynthesis orarthroplasty)
proxy or care giver knowing baseline cognitive status of the patient present orreachable by phone for an interview
Exclusion
Exclusion Criteria:
Patient already taking Melatonin
Contraindications and precaution for use of Melatonin administration:
Hypersensitivity to the active substance or to any of the excipients ofCircadin©
Liver failure (presence of some of the following clinical and biologicalsymptoms: icterus, asterixis, ascites, known esophageal varices, totalbilirubin >20 micromol/L, FV <70%),
Cirrhosis (known histological liver fibrosis)
Renal failure with clearance <30 ml/min O Autoimmune disease O Hereditarygalactose intolerance, Lapp lactase deficiency or glucose-galactosemalabsorption syndrome
Patients taking fluvoxamine, 5- or 8-methoxypsoralen, cimetidine,oestrogenotherapy, quinolones, carbamazepine, rifampicin
Other concomitant trauma than lower limb fracture(s)
Surgery scheduled in more than 5 days
Patient under mechanical ventilation
Patient refusing to participate
Patient not talking / understanding French (delirium assessment impossible)
Patient already participating to another interventional study
No signed informed consent,
No affiliation to a social security regime
Secondary Exclusion Criteria:
Secondary exclusion (before randomization): diagnosis of delirium at the CAM assessment at inclusion, or creatinin clearance <30 ml / min and /or biological signs of hepatocellular insufficiency (bilirubin> 20 umol/l and factor V <70%) if samples not available during the anesthesiologist consultation and so performed after inclusion.
Study Design
Study Description
Connect with a study center
hôpital Beaujon
Clichy-sous-Bois, 93390
FranceSite Not Available
hôpital Beaujon
Clichy-sous-Bois 3024596, 93390
FranceSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.